{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:15:55Z","timestamp":1788790555397,"version":"build-2803163510"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cervical cancer remains a leading cause of cancer death in women, and outcomes in recurrent or metastatic disease remain poor despite chemoradiation and bevacizumab. The HPV-driven biology that defines the disease\u2014viral E6\/E7 oncoproteins, an inflamed microenvironment and exploitable surface antigens\u2014has enabled a rapid expansion of novel systemic therapies, yet existing reviews tend to catalogue these agents by class or report individual trials in isolation, leaving their comparative efficacy, safety and clinical positioning unresolved. Here we organise emerging anti-tumour agents by mechanism of action and array them along a translational maturity gradient, from approved regimens through phase 1\/2 candidates to preclinical assets, appraising efficacy and safety in parallel. We cover immune checkpoint inhibitors, bispecific antibodies, antibody\u2013drug conjugates (ADCs), therapeutic HPV vaccines and adoptive cell therapy, and integrate China-developed agents\u2014including the PD-1\/CTLA-4 bispecific cadonilimab and the Nectin-4 conjugate 9MW2821\u2014into the global landscape. Departing from a purely descriptive account, we compare class-specific toxicity profiles and predictive biomarkers side by side and, most importantly, translate the fragmented evidence into a resistance-directed treatment framework anchored on platinum-resistant disease. We further argue that, because access to newly approved agents varies widely between health systems, the line of therapy at which an agent is introduced\u2014rather than its approval status alone\u2014may influence survival, a decision-relevant question that current guidelines leave unanswered. This mechanism-based, decision-oriented synthesis is intended to guide rational agent selection, sequencing and combination strategy across diverse clinical settings.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1948148","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:18:30Z","timestamp":1788787110000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond approval: a mechanism-based review of novel anti-tumour agents in cervical cancer and when to use them"],"prefix":"10.3389","volume":"17","author":[{"given":"Chenguang","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Gynaecology and Obstetrics, Affiliated Xuancheng Hospital of Wannan Medical University","place":["Xuancheng, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Song","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Affiliated Xuancheng Hospital of Wannan Medical University","place":["Xuancheng, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Gynaecology and Obstetrics, Affiliated Xuancheng Hospital of Wannan Medical University","place":["Xuancheng, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gynaecology and Obstetrics, Affiliated Xuancheng Hospital of Wannan Medical University","place":["Xuancheng, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xialing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Gynaecology and Obstetrics, Affiliated Xuancheng Hospital of Wannan Medical University","place":["Xuancheng, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Statistics, School of Public Health, Medical College, Zhejiang University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90409-8","article-title":"The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53","volume":"63","author":"Scheffner","year":"1990","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00546.x","article-title":"Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins","volume":"98","author":"Narisawa-Saito","year":"2007","journal-title":"Cancer Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.12749","article-title":"Revised FIGO staging for carcinoma of the cervix uteri","volume":"145","author":"Bhatla","year":"2019","journal-title":"Int J Gynaecol Obstet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0140-6736(20)30157-4","article-title":"Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Canfell","year":"2020","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904153401501","article-title":"Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer","volume":"340","author":"Morris","year":"1999","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904153401502","article-title":"Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer","volume":"340","author":"Rose","year":"1999","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nature21386","article-title":"Integrated genomic and molecular characterization of cervical cancer","volume":"543","year":"2017","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102453","article-title":"Co-expression of tissue factor, TROP2, and NECTIN4 in primary and matched metastatic cervical cancer lesions","volume":"59","author":"Ulvang","year":"2025","journal-title":"Transl Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5410","article-title":"Pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer: subgroup analyses from the KEYNOTE-826 randomized clinical trial","volume":"10","author":"Tewari","year":"2024","journal-title":"JAMA Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.annonc.2024.10.002","article-title":"Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study","volume":"36","author":"Lorusso","year":"2025","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00739","article-title":"Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II CheckMate 358 trial","volume":"37","author":"Naumann","year":"2019","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01808-7","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000002058","article-title":"Interobserver agreement on the interpretation of programmed death-ligand 1 (PD-L1) combined positive score (CPS) among gynecologic pathologists","volume":"47","author":"Mills","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0000000000000975","article-title":"Programmed death ligand-1 (PD-L1) expression in cervical squamous cell carcinoma: does it correlate with outcomes","volume":"42","author":"Monsrud","year":"2023","journal-title":"Int J Gynecol Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00894-y","article-title":"Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial","volume":"6","author":"Marabelle","year":"2025","journal-title":"Nat Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2010.07.044","article-title":"HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells","volume":"407","author":"Campo","year":"2010","journal-title":"Virology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3162","article-title":"Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): a phase 2 study","volume":"30","author":"Lou","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1038\/s41467-026-69965-1","article-title":"Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial","volume":"17","author":"Sun","year":"2026","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","first-page":"100558","DOI":"10.1016\/j.medj.2024.11.011","article-title":"Integrating CTLA-4\/PD-1 blockade into cervical cancer management: Results of COMPASSION-16","volume":"6","author":"How","year":"2025","journal-title":"Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02067","article-title":"Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase II study","volume":"40","author":"O'Malley","year":"2022","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00084","article-title":"Abscobal effect of balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer","volume":"40","author":"Aslan","year":"2022","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2026.02.008","article-title":"Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205\/ENGOT-cx8\/GOG-3024 study","author":"Van Nieuwenhuysen","year":"2026","journal-title":"Gynecol Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2026.37.e65","article-title":"Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses","volume":"37","author":"Lee","year":"2026","journal-title":"J Gynecol Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02975-x","article-title":"Efficacy of trastuzumab deruxtecan in HER2-expressing solid tumors by enrollment HER2 IHC status: post hoc analysis of DESTINY-PanTumor02","volume":"41","author":"Oaknin","year":"2024","journal-title":"Adv Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cjp2.184","article-title":"An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the International Endocervical Adenocarcinoma Criteria and Classification","volume":"7","author":"Shi","year":"2021","journal-title":"J Pathol Clin Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0000000000001068","article-title":"Molecular and clinicopathologic characterization of HER2-overexpressed squamous cell carcinoma of the cervix","volume":"44","author":"Mendoza","year":"2025","journal-title":"Int J Gynecol Pathol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0743","article-title":"Preclinical evaluation of 9MW2821, a site-specific monomethyl auristatin E-based antibody-drug conjugate for treatment of Nectin-4-expressing cancers","volume":"22","author":"Zhou","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.110816","article-title":"Structural basis of nectin-4 recognition by the antibody-drug conjugate 9MW2821","volume":"301","author":"Fang","year":"2025","journal-title":"J Biol Chem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/s41598-020-58009-3","article-title":"Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan","volume":"10","author":"Zeybek","year":"2020","journal-title":"Sci Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-2440","article-title":"An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors","volume":"74","author":"Breij","year":"2014","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00749","article-title":"Lysosomal P-gp-MDR1 confers drug resistance of brentuximab vedotin and its cytotoxic payload monomethyl auristatin E in tumor cells","volume":"10","author":"Liu-Kreyche","year":"2019","journal-title":"Front Pharmacol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1927","article-title":"A therapeutic antigen-presenting cell-targeting DNA vaccine VB10.16 in HPV16-positive high-grade cervical intraepithelial neoplasia: results from a phase I\/IIa trial","volume":"28","author":"Hillemanns","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.11.002","article-title":"First-in-human phase I clinical trial of an SFV-based RNA replicon cancer vaccine against HPV-induced cancers","volume":"29","author":"Komdeur","year":"2021","journal-title":"Mol Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000001235","article-title":"A randomized phase 2 study of ADXS11-001 Listeria monocytogenes-listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer","volume":"28","author":"Basu","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1881","article-title":"Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity","volume":"14","author":"Kenter","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.06.493","article-title":"Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: an NRG oncology\/gynecologic oncology group study","volume":"158","author":"Huh","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30486-1","article-title":"Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial","volume":"21","author":"Youn","year":"2020","journal-title":"Lancet Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovi\u0107","year":"2015","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2722","article-title":"A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers","volume":"25","author":"Stevanovi\u0107","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"7581","DOI":"10.1038\/s41467-022-35133-4","article-title":"A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma","volume":"13","author":"Xia","year":"2022","journal-title":"Nat Commun"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02091","article-title":"Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase II trial","volume":"40","author":"Xu","year":"2022","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12916-025-04198-5","article-title":"Long-term efficacy and updated survival outcomes of sintilimab plus anlotinib in patients with PD-L1-positive recurrent or metastatic cervical cancer","volume":"23","author":"Liu","year":"2025","journal-title":"BMC Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1142256","article-title":"Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study","volume":"14","author":"An","year":"2023","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102274","article-title":"Efficacy and safety of sintilimab plus albumin-bound-paclitaxel in recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II trial","volume":"65","author":"Wang","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41392-025-02294-9","article-title":"Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3\/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study","volume":"10","author":"Sheng","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00463-0","article-title":"Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey","volume":"22","author":"Fundytus","year":"2021","journal-title":"Lancet Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.921093","article-title":"Impact of the National Reimbursement Drug List Negotiation Policy on accessibility of anticancer drugs in China: an interrupted time series study","volume":"10","author":"Zhu","year":"2022","journal-title":"Front Public Health"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ijgo.13484","article-title":"WHO global strategy to eliminate cervical cancer as a public health problem: an opportunity to make it a disease of the past","volume":"152","author":"Simelela","year":"2021","journal-title":"Int J Gynaecol Obstet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1948148\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:18:31Z","timestamp":1788787111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1948148\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":73,"alternative-id":["10.3389\/fimmu.2026.1948148"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1948148","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"1948148"}}